

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
6124362.pn. and pH	1

Database:

US Patents Full-Text Database ▲
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins ▼

Search:

scalp.ab. and pH

[Refine Search](#)[Recall Text](#) ⇐[Clear](#)**Search History****DATE:** Sunday, September 29, 2002 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
---------------------------------	--------------	------------------	-------------------------------

DB=USPT; PLUR=YES; OP=OR

<u>L1</u>	6124362.pn. and pH	1	<u>L1</u>
-----------	--------------------	---	-----------

END OF SEARCH HISTORY

Derwent World Patents Index

09/917,215

June 17, 2002

=> d que

L22

75 SEA PROSTAGLANDIN (3A) (EP2 OR EP3 OR EP 4 OR EP4 OR EP 2 OR EP 3)

L23

5 SEA L22 AND (ALOPECIA OR HAIR?)

spec.
lack of written description
EP - argument
No response
do mo' search

L23 ANSWER 1 OF 5 WPIX (C) 2002 THOMSON DERWENT
 AN 2002-306252 [35] WPIX
 DNC C2002-089282
 TI Cosmetic composition for reducing or terminating **hair** loss, containing **prostaglandin EP-3** receptor antagonist as stable, non-toxic, non-irritating **hair** growth stimulant.
 DC A96 B05 D21
 IN BERNARD, B; MAHE, Y; MICHELET, J; MICHELET, J F
 PA (OREA) L'OREAL SA; (BERN-I) BERNARD B; (MAHE-I) MAHE Y; (MICH-I) MICHELET J F
 CYC 28
 PI EP 1175892 A1 20020130 (200235)* FR 12p
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
 CA 2354110 A1 20020128 (200235) FR
 FR 2812192 A1 20020201 (200235)
 US 2002052416 A1 20020502 (200236)
 ADT EP 1175892 A1 EP 2001-401976 20010723; CA 2354110 A1 CA 2001-2354110 20010725; FR 2812192 A1 FR 2000-9985 20000728; US 2002052416 A1 US 2001-917215 20010730
 PRAI FR 2000-9985 20000728
 AN 2002-306252 [35] WPIX
 AB EP 1175892 A UPAB: 20020603
 NOVELTY - A cosmetic composition (A) comprises at least one **prostaglandin EP-3** receptor antagonist (I) in a cosmetic medium.
 ACTIVITY - Antialopecia.
 MECHANISM OF ACTION - **Prostaglandin EP-3** receptor antagonist.
 USE - The use of (A), or the active agent (I), is claimed for attenuating, reducing or terminating **hair** loss; corresponding anti-**hair** loss treatment methods are also claimed.
 ADVANTAGE - (I) induce and stimulate the growth of **hair** and strongly retard **hair** loss. They have rapid action; are effective at low concentration and/or at a low frequency of application; are stable and non-toxic; are easy to apply and rinse off; and cause no irritation on prolonged contact with the scalp, even if not rinsed off.
 Dwg.0/0

L23 ANSWER 2 OF 5 WPIX (C) 2002 THOMSON DERWENT
 AN 2002-306251 [35] WPIX
 DNC C2002-089281
 TI Cosmetic composition for reducing or terminating **hair** loss, containing non-prostanoid **prostaglandin EP-2** and/or EP-4 receptor agonist as stable, non-toxic, non-irritating **hair** growth stimulant.
 DC A96 B05 D21
 IN BERNARD, B; MAHE, Y; MICHELET, J; MICHELET, J F
 PA (OREA) L'OREAL SA; (BERN-I) BERNARD B; (MAHE-I) MAHE Y; (MICH-I) MICHELET J F
 CYC 28
 PI EP 1175891 A1 20020130 (200235)* FR 11p
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
 CA 2354109 A1 20020128 (200235) FR

FR 2812190 A1 20020201 (200235)
 US 2002044953 A1 20020418 (200235)
 ADT EP 1175891 A1 EP 2001-401975 20010723; CA 2354109 A1 CA 2001-2354109
 20010725; FR 2812190 A1 FR 2000-9981 20000728; US 2002044953 A1 US
 2001-917236 20010730
 PRAI FR 2000-9981 20000728
 AN 2002-306251 [35] WPIX
 AB EP 1175891 A UPAB: 20020603
 NOVELTY - A cosmetic composition (A) comprises at least one non-prostanoid
prostaglandin EP-2 and/or EP-4 receptor
 agonist (I) in a cosmetic medium.
 ACTIVITY - Antialopecia.
 MECHANISM OF ACTION - **Prostaglandin EP-2**
 and/or EP-4 receptor agonist.
 USE - The use of (A), or the active agent (I), is claimed for
 attenuating, reducing or terminating **hair** loss; corresponding
 anti-**hair** loss treatment methods are also claimed.
 ADVANTAGE - (I) induce and stimulate the growth of **hair** and
 strongly retard **hair** loss. They have rapid action; are effective
 at low concentration and/or at a low frequency of application; are stable
 and non-toxic; are easy to apply and rinse off; and cause no irritation on
 prolonged contact with the scalp, even if not rinsed off.
 Dwg.0/0

L23 ANSWER 3 OF 5 WPIX (C) 2002 THOMSON DERWENT
 AN 2002-306250 [35] WPIX
 DNC C2002-089280
 TI Reducing or terminating **hair** loss, using **prostaglandin**
EP-3 receptor agonist as stable, non-toxic,
 non-irritating cosmetic **hair** growth stimulant.
 DC A96 B05 D21
 IN BERNARD, B; MAHE, Y; MICHELET, J; MICHELET, J F
 PA (OREA) L'OREAL SA; (BERN-I) BERNARD B; (MAHE-I) MAHE Y; (MICH-I) MICHELET
 J F
 CYC 28
 PI EP 1175890 A1 20020130 (200235)* FR 11p
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI TR
 CA 2354108 A1 20020128 (200235) FR
 FR 2812191 A1 20020201 (200235)
 US 2002045659 A1 20020418 (200235)
 ADT EP 1175890 A1 EP 2001-401974 20010723; CA 2354108 A1 CA 2001-2354108
 20010725; FR 2812191 A1 FR 2000-9983 20000728; US 2002045659 A1 US
 2001-917274 20010730
 PRAI FR 2000-9983 20000728
 AN 2002-306250 [35] WPIX
 AB EP 1175890 A UPAB: 20020603
 NOVELTY - The use of **prostaglandin EP-3**
 receptor agonists (I) is claimed as cosmetic agents for attenuating,
 reducing or terminating **hair** loss.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:
 (i) the use of (I) in (or for the preparation of) a topical cosmetic
 composition (A) for use as above; and
 (ii) corresponding anti-**hair** loss treatment methods,
 involving application of (I) or (A).
 ACTIVITY - Antialopecia.
 MECHANISM OF ACTION - **Prostaglandin EP-3**

receptor agonist.

USE - For attenuating, reducing or terminating **hair** loss.

ADVANTAGE - (I) induce and stimulate the growth of **hair** and strongly retard **hair** loss. They have rapid action; are effective at low concentration and/or at a low frequency of application; are stable and non-toxic; are easy to apply and rinse off; and cause no irritation on prolonged contact with the scalp, even if not rinsed off.
Dwg.0/0

L23 ANSWER 4 OF 5 WPIX (C) 2002 THOMSON DERWENT

AN 2002-306249 [35] WPIX

DNC C2002-089279

TI Reducing or terminating **hair** loss, using **prostaglandin EP-2** and/or EP-4 receptor antagonist as stable, non-toxic, non-irritating cosmetic **hair** growth stimulant.

DC A96 B05 D21

IN BERNARD, B; MAHE, Y; MICHELET, J; MICHELET, J F

PA (OREA) L'OREAL SA; (BERN-I) BERNARD B; (MAHE-I) MAHE Y; (MICH-I) MICHELET J F

CYC 29

PI EP 1175889 A1 20020130 (200235)* FR 11p

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR

CA 2354117 A1 20020128 (200235) FR

FR 2812193 A1 20020201 (200235)

JP 2002053438 A 20020219 (200235)

6p

US 2002052414 A1 20020502 (200236)

ADT EP 1175889 A1 EP 2001-401973 20010723; CA 2354117 A1 CA 2001-2354117 20010725; FR 2812193 A1 FR 2000-9986 20000728; JP 2002053438 A JP 2001-229703 20010730; US 2002052414 A1 US 2001-917211 20010730

PRAI FR 2000-9986 20000728

AN 2002-306249 [35] WPIX

AB EP 1175889 A UPAB: 20020603

NOVELTY - The use of **prostaglandin EP-2**

and/or EP-4 receptor antagonists (I) is claimed as cosmetic agents for attenuating, reducing or terminating **hair** loss.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:

(i) the use of (I) in (or for the preparation of) a topical cosmetic composition (A) for use as above; and

(ii) corresponding anti-**hair** loss treatment methods, involving application of (I) or (A).

ACTIVITY - Antialopecia.

MECHANISM OF ACTION - **Prostaglandin EP-2** and/or EP-4 receptor antagonist.

USE - For attenuating, reducing or terminating **hair** loss.

ADVANTAGE - (I) induce and stimulate the growth of **hair** and strongly retard **hair** loss. They have rapid action; are effective at low concentration and/or at a low frequency of application; are stable and non-toxic; are easy to apply and rinse off; and cause no irritation on prolonged contact with the scalp, even if not rinsed off.
Dwg.0/0

L23 ANSWER 5 OF 5 WPIX (C) 2002 THOMSON DERWENT

AN 2001-662910 [76] WPIX

DNC C2001-194706

TI Agents for controlling **hair** growth or **hair** formation comprise a **prostaglandin EP4** receptor agonist.

DC B02 D21 E13
IN HAYASHI, R; ISOGAYA, M; KUMAGAI, H; MORI, T; YAMADA, N
PA (TORA) TORAY IND INC
CYC 26
PI WO 2001072268 A1 20011004 (200176)* JA 79p
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
W: AU CA CN JP KR US
AU 2001044669 A 20011008 (200208).....
EP 1186287 A1 20020313 (200225) EN
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
ADT WO 2001072268 A1 WO 2001-JP2756 20010330; AU 2001044669 A AU 2001-44669
20010330; EP 1186287 A1 EP 2001-917702 20010330, WO 2001-JP2756 20010330
FDT AU 2001044669 A Based on WO 200172268; EP 1186287 A1 Based on WO 200172268
PRAI JP-2000-97542 20000331
AN 2001-662910 [76] WPIX
AB WO 200172268 A UPAB: 20011227
NOVELTY - Agents for controlling **hair** growth or **hair**
formation comprise a **prostaglandin EP4** receptor
agonist.
ACTIVITY - Dermatological.
An example of (I) administered at 0.1 mg/kg for 20 days increased
hair growth from 4.8 mm for a control to 7.3 mm.
MECHANISM OF ACTION - **Prostaglandin-Agonist-EP4**.
USE - For controlling **hair** growth or **hair**
formation e.g. for promoting **hair** growth or **hair**
formation.
Dwg.0/0